ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma

Future Oncology

Volumn 9, Issue 5, 2013, Pages 737-745

  Giacalone, Nicholas J ^a   Den, Robert B ^b   Eisenberg, Rosana ^a   Chen, Heidi ^a   Olson, Sandra J ^a   Massion, Pierre P ^a   Carbone, David P ^a   Lu, Bo ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ALDH family; ALDH7A1; biomarker; non small cell lung carcinoma; recurrence

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 7A1; UNCLASSIFIED DRUG;

ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY;

ALDEHYDE DEHYDROGENASE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 84877608636     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.19     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Manser R, Wright G, Hart D, Byrnes G, Campbell DA. Surgery for early stage non-small cell lung cancer. Cochrane Database Syst. Rev. 1, CD004699 (2005).
3. Eramo A, Haas Tl, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29(33), 4625-4635 (2010).
4. Alison MR, Guppy NJ, Lim SM, Nicholson LJ. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J. Pathol. 222(4), 335-344 (2010).
5. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 7(3), 330-338 (2009).
6. Deng S, Yang X, Lassus H, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5(4), e10277 (2010).
7. van den Hoogen C, van der Horst G, Cheung H, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 70(12), 5163-5173 (2010).
8. Prokopczyk B, Sinha I, Trushin N, Freeman WM, El-Bayoumy K. Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4 (methylnitrosamino)-1 (3 pyridyl)-1 butanone. Chem. Biol. Interact. 177(3), 173-180 (2009).
9. Rose AE, Poliseno L, Wang J, et al. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res. 71(7), 2561-2571 (2011).
10. Chan CL, Wong JW, Wong CP, Chan MK, Fong WP. Human antiquitin: structural and functional studies. Chem. Biol. Interact. 191(1-3), 165-170 (2010).
11. Albert JM, Gonzalez A, Massion PP, et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol. Biomarkers Prev. 16(9), 1845-1851 (2007).
12. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 414(6859), 105-111 (2001).
13. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 66(4), 1883-1890; discussion 1895-1886 (2006).
14. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8(7), 545-554 (2008).
15. Ghotra VP, Puigvert JC, Danen EH. The cancer stem cell microenvironment and anti-cancer therapy. Int. J. Radiat. Biol. 85(11), 955-962 (2009).
16. Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M, Stassi G. Therapeutic implications of cancer initiating cells. Expert Opin. Biol. Ther. 9(8), 1005-1016 (2009).
17. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15(3), 504-514 (2008).
18. Tirino V, Camerlingo R, Franco R, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 36(3), 446-453 (2009).
19. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl Acad. Sci. USA 106(38), 16281-16286 (2009).
20. Woo T, Okudela K, Mitsui H, et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int. J. Clin. Exp. Pathol. 4(1), 32-42 (2010).
21. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer 59(3), 340-349 (2008).
22. Moreb JS, Baker HV, Chang LJ, et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol. Cancer 7, 87 (2008).
23. Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 70(23), 9937-9948 (2010).
24. Brocker C, Cantore M, Failli P, Vasiliou V. Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity. Chem. Biol. Interact. 191(1-3), 269-277 (2011).
25. Brocker C, Lassen N, Estey T, et al. Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. J. Biol. Chem. 285(24), 18452-18463 (2010).
26. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G. The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin. Exp. Metastasis 28(7), 615-625 (2011).
27. Comporti M. Lipid peroxidation and biogenic aldehydes: from the identification of 4 hydroxynonenal to further achievements in biopathology. Free Radic. Res. 28(6), 623-635 (1998).
28. Takahashi Y, Ogra Y, Suzuki KT. Synchronized generation of reactive oxygen species with the cell cycle. Life Sci. 75(3), 301-311 (2004).
29. Havens CG, Ho A, Yoshioka N, Dowdy SF. Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol. Cell Biol. 26(12), 4701-4711 (2006).
30. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94(6), 2056-2064 (1999).
31. Cicalese A, Bonizzi G, Pasi CE, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138(6), 1083-1095 (2009).
32. Richardson ME, Siemann DW. Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. Int. J. Radiat. Oncol. Biol. Phys. 39(4), 789-795 (1997).